Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company`s lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia`s Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Website: cel-sci.com


  • Bad financial results growth rate 0.0% (average between last period year over year growth for revenue and EBITDA), are preserved at an average historical level (0.0%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 5.2% (LTM)
  • Share price is 3 130.5% higher than minimum and 52.6% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 1.1x)

Key Financials (Download financials)

Ticker: CVM
Share price, USD:  (0.0%)6.18
year average price 4.85  


year start price 0.42 2025-02-14

min close price 0.19 2025-04-08

max close price 13.04 2025-08-27

current price 6.18 2026-02-13
Common stocks: 84 540 132

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):

Target EV / EBITDA (hist percentile): 1.1x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 522
Net Debt ($m): -33
EV (Enterprise Value): 489
EBITDA LTM (млн $): -15
Price to Book: 32.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-08-30globenewswire.com

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

2023-07-18InvestorPlace

Why Is CEL-SCI (CVM) Stock Down 23% Today?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q3
date 2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-09-30
symbol CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363
filingDate 2025-12-29 2025-01-13 2023-12-21 2022-12-27 2021-12-21
acceptedDate 2025-12-23 17:36:36 2025-08-14 09:31:38 2025-05-14 16:20:57 2025-01-13 16:16:33 2024-08-14 16:27:32 2024-05-15 16:17:31 2024-02-14 16:31:12 2023-12-21 16:15:39 2023-08-10 16:10:28 2023-05-12 16:11:55 2023-02-14 16:16:36 2022-12-27 16:15:57 2021-12-21 16:33:58
fiscalYear 2025 2024 2023 2022 2021
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
revenue 0 0 0 0 0 0 0 0 0 0 0 0 0
costOfRevenue 4M 959 009 970 102 4M 983 208 988 762 1M 4M 0 0 0 4M 499 000
grossProfit -4M -959 009 -970 102 -4M -983 208 -988 762 -1M -4M 0 0 0 -4M -499 000
researchAndDevelopmentExpenses 16M 4M 4M 18M 5M 5M 4M 22M 6M 6M 5M 25M 23M
generalAndAdministrativeExpenses 0 2M 2M 8M 2M 2M 2M 9M 2M 2M 2M 11M 13M
sellingAndMarketingExpenses 0 0 0 0 0 -988 762 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 2M 1M 4M 2M 1M 2M 9M 2M 2M 2M 11M 13M
otherExpenses 0 -959 009 0 0 0 13 758 -25 941 -22M -3854 -7500 -50 171 76 355 2M
operatingExpenses 21M 5M 5M 22M 7M 6M 6M 31M 8M 8M 8M 36M 36M
costAndExpenses 25M 5M 6M 26M 7M 7M 6M 31M 8M 8M 8M 36M 36M
netInterestIncome -648 944 -745 673 -674 741 -1M -1M
interestIncome 0 0 0 0 0 0 0 675.416 0 0 0 1081.034 1125.288
interestExpense 648 944 172 050 178 286 745 673 190 705 182 701 197 696 675 416 181 670 159 063 152 789 1M 1M
depreciationAndAmortization 4M 959 009 970 102 4M 984 208 988 762 1M 4M 985 699 977 939 938 372 4M 499 000
ebitda -21M -5M -5M -22M -6M -6M -6M -28M -7M -7M -7M -32M -35M
ebit -25M -26M -32M -36M -35M
nonOperatingIncomeExcludingInterest -47 620 -177 680 42 810 -443 148 -982 120
operatingIncome -25M -5M -6M -26M -7M -7M -6M -31M -8M -8M -8M -36M -36M
totalOtherIncomeExpensesNet -601 319 -175 821 -178 286 -567 991 -186 323 -168 943 -25 941 -718 228 -3854 -166 563 -374 512 -637 888 -166 980
incomeBeforeTax -25M -6M -7M -27M -7M -7M -7M -32M -8M -8M -8M -37M -36M
incomeTaxExpense 0 0 0 0 0 -2 171 755 0 177 816 166 563 374 512 2M 3M
netIncomeFromContinuingOperations -25M -27M -32M -38M -37M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 -171 553 929 122 350 861
netIncome -25M -6M -7M -27M -7M -7M -7M -32M -8M -9M -8M -38M -39M
netIncomeDeductions 0 659 456 171 552 929 122 350 861
bottomLineNetIncome -25M -28M -32M -38M -37M
eps -6.27 -1.36 -2.33 -13.5 -0.14 -0.14 -0.14 -21.9 -0.19 -0.2 -0.19 -26.7 -28.8
epsDiluted -6.27 -13.5 -21.9 -26.7 -28.8
weightedAverageShsOut 4M 4M 3M 2M 54M 52M 48M 1M 44M 44M 43M 1M 1M
weightedAverageShsOutDil 4M 4M 3M 2M 54M 52M 48M 1M 44M 44M 44M 1M 1M
fillingDate 2025-08-14 2025-05-14 2024-08-14 2024-05-15 2024-02-14 2023-08-10 2023-05-12 2023-02-14
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023
grossProfitRatio 0 0 0 0 0 0 0 0
ebitdaratio 0 0 0 0 0 0 0 0
operatingIncomeRatio 0 0 0 0 0 0 0 0
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0
netIncomeRatio 0 0 0 0 0 0 0 0
epsdiluted -1.36 -2.33 -0.14 -0.14 -0.14 -0.19 -0.2 -0.19
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q3
date 2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-09-30
symbol CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363
filingDate 2025-12-29 2025-01-13 2023-12-21 2022-12-27 2021-12-21
acceptedDate 2025-12-23 17:36:36 2025-08-14 09:31:38 2025-05-14 16:20:57 2025-01-13 16:16:33 2024-08-14 16:27:32 2024-05-15 16:17:31 2024-02-14 16:31:12 2023-12-21 16:15:39 2023-08-10 16:10:28 2023-05-12 16:11:55 2023-02-14 16:16:36 2022-12-27 16:15:57 2021-12-21 16:33:58
fiscalYear 2025 2024 2023 2022 2021
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
cashAndCashEquivalents 10 953M 2M 2M 5M 384 652 5M 3M 4M 5M 10M 18M 23M 36M
shortTermInvestments 0 7500 0 0 0 16 129 16.129 0 0 0 0 0 6M
cashAndShortTermInvestments 10 953M 2M 2M 5M 384 652 5M 3M 4M 5M 10M 18M 23M 42M
netReceivables 0 0 0 0 0 0 -2M 0 -2M -2M -2M 0 54 922
accountsReceivables 0 0 0 0 54 922
otherReceivables 0 0 0 0 0
inventory 0 518 040 882 692 1M 3M 2M 2M 2M 2M 2M 2M 2M 2M
prepaids 0 294 097 520 368 762 063 998 482
otherCurrentAssets 643M 311 633 215 962 3500 602 466 696 648 3M 4245 3M 3M 2M 0 0
totalCurrentAssets 11 596M 3M 3M 6M 4M 9M 6M 7M 8M 13M 20M 25M 45M
propertyPlantEquipmentNet 12 902M 14M 15M 17M 18M 19M 20M 21M 22M 23M 24M 25M 28M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 119 856 130 585 141 263 165 492 173 028 180 482 188 294 197 704 183 074 192 231 202 070 212 201 275 866
goodwillAndIntangibleAssets 119 856 130 585 141 263 165 492 173 028 180 482 188 294 197 704 183 074 192 231 202 070 212 201 275 866
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 3 657M 4M 4M 4M 2M 2M 2M 2M 2M 2M 104 607 164 299 2M
totalNonCurrentAssets 16 560M 18M 19M 21M 21M 22M 23M 24M 25M 26M 24M 25M 31M
otherAssets 0 0 0 0 0 0 -0 0 0 0 0 0 0
totalAssets 28 156M 20M 22M 27M 24M 30M 29M 31M 32M 38M 45M 51M 76M
totalPayables 1M 1M 2M 2M 2M
accountPayables 1M 2M 2M 1M 1M 1M 1M 2M 2M 2M 2M 2M 2M
otherPayables 0 0 0 0 0
accruedExpenses 0 566 042 2M 842 492 859 216
shortTermDebt 2 441M 2M 5M 2M 4M 2M 2M 0 2M 2M 2M 0 0
capitalLeaseObligationsCurrent 0 2M 2M 2M 698 665
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 1 0 0 0 0 0 0 1M
otherCurrentLiabilities 2 689M 2M -895 794 -2M -199 628 2M 2M 0 2M 2M 1M 471 488 -421 836
totalCurrentLiabilities 5 131M 6M 5M 5M 6M 5M 5M 6M 5M 5M 5M 5M 4M
longTermDebt 6 943M 8M 8M 0 10M 11M 11M 0 12M 13M 13M 0 0
capitalLeaseObligationsNonCurrent 7M 9M 12M 14M 15M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 125M 125 000 125 000 125 000 125 000 124 999 125 000 125 000 125 000 125 000 125 000 125 000 125 000
totalNonCurrentLiabilities 7 068M 8M 8M 10M 10M 11M 11M 12M 12M 13M 13M 14M 15M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 7M 10M 11M 12M 12M 13M 13M 14M 14M 14M 15M 15M 16M
totalLiabilities 12 199M 13M 14M 14M 16M 16M 16M 17M 18M 18M 18M 18M 19M
treasuryStock 0 0 0 0 0
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 80 157 53 214 843 496 637 870 542 578 540 837 500 186 474 223 447 484 437 878 437 256 434 484 432 072
retainedEarnings -539M -533M -528M -514M -508M -501M -494M -487M -479M -471M -463M -455M -418M
additionalPaidInCapital 555M 526M 500M 487M 474M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0 0 0 0 0 0 0 0
otherTotalStockholdersEquity 0 0 0 0 0
totalStockholdersEquity 16M 7M 8M 13M 8M 14M 13M 13M 15M 20M 27M 32M 57M
totalEquity 15 957M 7M 8M 13M 8M 14M 13M 13M 15M 20M 27M 32M 57M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 28 156M 20M 22M 27M 24M 30M 29M 31M 32M 38M 45M 51M 76M
totalInvestments 0 7500 0 0 51 129 16 129 16.129 0 0 0 0 0 6M
totalDebt 9 384M 10M 11M 12M 12M 13M 13M 14M 14M 14M 15M 15M 16M
netDebt -1 570M 8M 9M 7M 12M 7M 10M 9M 9M 4M -3M -7M -20M
fillingDate 2025-08-14 2025-05-14 2024-08-14 2024-05-15 2024-02-14 2023-08-10 2023-05-12 2023-02-14
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023
othertotalStockholdersEquity 540M 535M 516M 515M 506M 494M 491M 489M
totalLiabilitiesAndStockholdersEquity 20M 22M 24M 30M 29M 32M 38M 45M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q3
date 2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-09-30
symbol CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363
filingDate 2025-12-29 2025-01-13 2023-12-21 2022-12-27 2021-12-21
acceptedDate 2025-12-23 17:36:36 2025-08-14 09:31:38 2025-05-14 16:20:57 2025-01-13 16:16:33 2024-08-14 16:27:32 2024-05-15 16:17:31 2024-02-14 16:31:12 2023-12-21 16:15:39 2023-08-10 16:10:28 2023-05-12 16:11:55 2023-02-14 16:16:36 2022-12-27 16:15:57 2021-12-21 16:33:58
fiscalYear 2025 2024 2023 2022 2021
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
netIncome -25 411M -6M -7M -27M -7M -7M -7M -32M -8M -8M -8M -37M -36M
depreciationAndAmortization 3 885M 959 009 970 102 4M 984 208 988 762 1M 4M 985 699 985 439 988 543 4M 2M
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 713 624
stockBasedCompensation 1 911M 207 288 849 645 4M 1M 2M 2M 7M 2M 2M 2M 12M 14M
changeInWorkingCapital 1M 557 033 32 954 -1M 273 457 -88 962 -836 743 -2M -68 521 -2M 301 372 3M -483 474
accountsReceivables 0 0 0 0 0 0 0 444 780 0 0 0 54 922 497 077
inventory 973 665 416 649 12 340 -172 608 -64 030 -141 302 -98 765 -156 727 -194 925 -42 253 212 687 -159 430 -1M
accountsPayables -442 710 -101 765 -369 305 -460 576 304 569 -131 861 -765 078 257 845 -36 225 218 126 -115 285 374 890 445 981
otherWorkingCapital 631 460 242 149 389 919 -579 007 32 918 184 201 27 100 -2M 162 629 -2M 203 970 2M -240 000
otherNonCashItems 2 494M 1712 350 109 1M 35 625 4M 2504 15 293 3243 -144 391 153 936 480 117 1M
netCashProvidedByOperatingActivities -17 120M -4M -4M -19M -5M -5M -5M -23M -6M -7M -5M -18M -19M
investmentsInPropertyPlantAndEquipment -38M 0 0 -94 875 -23 472 0 -64 861 -361 892 -196 860 -111 452 -53 580 -660 633 -9M
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 -6M
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 6M 0
otherInvestingActivities 0 -13 211 -10 370 6129.259 -6168.405
netCashProvidedByInvestingActivities -38M -108 086 -372 262 5M -15M
netDebtIssuance -2M -2M -2M -600 041 534 154
longTermNetDebtIssuance -2M -2M -2M -600 041 534 154
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 25M 24M 7M 0 48M
netCommonStockIssuance 25M 24M 7M 0 48M
commonStockIssuance 25M 24M 7M -38 385 48M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0
netPreferredStockIssuance 0 0 -297 622 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 23 350M -2M -297 622 -38 385 6M
netCashProvidedByFinancingActivities 23 373M 20M 5M -638 426 55M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 6 215M -131 449 -3M 592 438 -5M 2M -904 295 -19M -5M -8M -5M -13M 21M
cashAtEndOfPeriod 10 953M 2M 2M 5M 384 652 5M 3M 4M 5M 10M 18M 23M 36M
cashAtBeginningOfPeriod 4 738M 2M 5M 4M 5M 3M 4M 23M 10M 18M 23M 36M 16M
operatingCashFlow -17 120M -4M -4M -19M -5M -5M -5M -23M -6M -7M -5M -18M -19M
capitalExpenditure -38M 0 0 -94 875 -23 477 0 -64 861 -372 262 -196 860 -111 452 -53 580 -660 633 -9M
freeCashFlow -17 158M -4M -4M -19M -5M -5M -5M -23M -6M -8M -5M -19M -28M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0
fillingDate 2025-08-14 2025-05-14 2024-08-14 2024-05-15 2024-02-14 2023-08-10 2023-05-12 2023-02-14
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023
otherInvestingActivites 0 0 0 0 -13.211 0 0 0
netCashUsedForInvestingActivites 0 0 -23 472 0 -64 861 -196 860 -111 452 -53 580
debtRepayment -510 346 -498 860 -448 283 -440 415 -426 593 -396 148 -388 352 -372 871
commonStockIssued 5M 3M 45 360 8M 5M 0 0 -9010
dividendsPaid 0 0 0 0 0 0 0 0
otherFinancingActivites -681 441 -381 371 125 980 -714 024 -504 913 1M 0 447 291
netCashUsedProvidedByFinancingActivities 4M 2M -322 303 7M 4M 951 563 -388 352 65 410
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Earning call transcript

SEC forms

Show financial reports only

SEC form 10
2025-12-23 22:36 ET
CEL-SCI Corporation reported for 2025 q3
SEC form 8
2025-11-24 22:00 ET
CEL-SCI Corporation published news for 2025 q3
SEC form 8
2025-11-24 22:00 ET
CEL-SCI Corporation published news for 2025 q3
SEC form 8
2025-11-05 21:31 ET
CEL-SCI Corporation published news for 2025 q3
SEC form 8
2025-11-05 21:31 ET
CEL-SCI Corporation published news for 2025 q3
SEC form 8
2025-08-29 17:15 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-08-29 17:15 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-08-29 17:15 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-08-29 17:15 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-08-29 17:15 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 10
2025-08-14 13:31 ET
CEL-SCI Corporation reported for 2025 q2
SEC form 8
2025-07-14 20:25 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-07-14 20:25 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-07-14 20:25 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-07-14 20:25 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-07-14 20:25 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-05-23 20:16 ET
CEL-SCI Corporation published news for 2025 q1
SEC form 8
2025-05-23 20:16 ET
CEL-SCI Corporation published news for 2025 q1
SEC form 8
2025-05-23 20:16 ET
CEL-SCI Corporation published news for 2025 q1
SEC form 8
2025-05-23 20:16 ET
CEL-SCI Corporation published news for 2025 q1
SEC form 8
2025-05-23 20:16 ET
CEL-SCI Corporation published news for 2025 q1
SEC form 10
2025-05-14 20:20 ET
CEL-SCI Corporation reported for 2025 q1
SEC form 10
2025-05-14 00:00 ET
CEL-SCI Corporation reported for 2025 q1
SEC form 8
2025-03-18 21:07 ET
CEL-SCI Corporation published news for 2024 q4
SEC form 8
2025-03-18 21:07 ET
CEL-SCI Corporation published news for 2024 q4
SEC form 8
2025-03-18 21:07 ET
CEL-SCI Corporation published news for 2024 q4
SEC form 8
2025-03-18 21:07 ET
CEL-SCI Corporation published news for 2024 q4
SEC form 8
2025-03-18 21:07 ET
CEL-SCI Corporation published news for 2024 q4
SEC form 8
2025-03-18 21:07 ET
CEL-SCI Corporation published news for 2024 q4
SEC form 10
2025-02-14 16:15 ET
CEL-SCI Corporation reported for 2024 q4
SEC form 10
2025-02-14 00:00 ET
CEL-SCI Corporation reported for 2024 q4
SEC form 10
2025-01-13 00:00 ET
CEL-SCI Corporation reported for 2024 q3
SEC form 10
2024-08-14 16:27 ET
CEL-SCI Corporation reported for 2024 q2
SEC form 10
2024-08-14 00:00 ET
CEL-SCI Corporation reported for 2024 q2
SEC form 10
2024-05-15 16:17 ET
CEL-SCI Corporation reported for 2024 q1
SEC form 10
2024-05-15 00:00 ET
CEL-SCI Corporation reported for 2024 q1
SEC form 10
2024-02-14 00:00 ET
CEL-SCI Corporation reported for 2023 q4
SEC form 10
2023-12-21 16:15 ET
CEL-SCI Corporation reported for 2023 q3
SEC form 10
2023-12-21 00:00 ET
CEL-SCI Corporation reported for 2023 q3
SEC form 10
2023-08-10 16:10 ET
CEL-SCI Corporation reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
CEL-SCI Corporation reported for 2023 q2
SEC form 6
2023-07-20 16:10 ET
CEL-SCI Corporation published news for 2023 q2
SEC form 6
2023-07-18 16:05 ET
CEL-SCI Corporation published news for 2023 q2
SEC form 6
2023-07-14 12:25 ET
CEL-SCI Corporation published news for 2023 q2
SEC form 6
2023-07-12 09:01 ET
CEL-SCI Corporation published news for 2023 q2
SEC form 10
2023-05-12 16:11 ET
CEL-SCI Corporation reported for 2023 q1
SEC form 10
2023-05-12 00:00 ET
CEL-SCI Corporation reported for 2023 q1
SEC form 6
2023-05-02 16:39 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-05-01 16:15 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-04-19 10:56 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-04-10 10:01 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-04-10 10:00 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-03-09 10:09 ET
CEL-SCI Corporation published news for 2022 q4
SEC form 10
2023-02-14 16:16 ET
CEL-SCI Corporation reported for 2022 q4
SEC form 10
2023-02-14 00:00 ET
CEL-SCI Corporation reported for 2022 q4
SEC form 10
2022-12-27 16:15 ET
CEL-SCI Corporation reported for 2022 q3
SEC form 10
2022-12-27 00:00 ET
CEL-SCI Corporation reported for 2022 q3
SEC form 6
2022-09-13 11:23 ET
CEL-SCI Corporation published news for 2022 q2
SEC form 6
2022-08-22 09:00 ET
CEL-SCI Corporation published news for 2022 q2
SEC form 10
2022-08-12 16:17 ET
CEL-SCI Corporation reported for 2022 q2
SEC form 10
2022-08-12 00:00 ET
CEL-SCI Corporation reported for 2022 q2
SEC form 6
2022-08-08 16:06 ET
CEL-SCI Corporation published news for 2022 q2
SEC form 6
2022-06-13 17:02 ET
CEL-SCI Corporation published news for 2022 q1
SEC form 10
2022-05-13 16:16 ET
CEL-SCI Corporation reported for 2022 q1
SEC form 10
2022-05-13 00:00 ET
CEL-SCI Corporation reported for 2022 q1
SEC form 6
2022-04-29 16:08 ET
CEL-SCI Corporation published news for 2022 q1
SEC form 6
2022-04-29 16:06 ET
CEL-SCI Corporation published news for 2022 q1
SEC form 10
2022-02-11 16:16 ET
CEL-SCI Corporation published news for 2021 q4
SEC form 10
2022-02-11 00:00 ET
CEL-SCI Corporation published news for 2021 q4
SEC form 10
2021-12-21 16:33 ET
CEL-SCI Corporation published news for 2021 q3
SEC form 10
2021-12-21 00:00 ET
CEL-SCI Corporation published news for 2021 q3
SEC form 10
2021-08-13 16:17 ET
CEL-SCI Corporation published news for 2021 q2
SEC form 10
2021-08-13 00:00 ET
CEL-SCI Corporation published news for 2021 q2
SEC form 6
2021-07-07 15:24 ET
CEL-SCI Corporation published news for 2021 q2
SEC form 6
2021-07-01 17:43 ET
CEL-SCI Corporation published news for 2021 q2
SEC form 6
2021-06-29 08:29 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 6
2021-06-09 16:09 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 6
2021-05-18 11:02 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 6
2021-05-18 11:00 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 10
2021-05-17 16:11 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 10
2021-05-17 00:00 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 10
2021-02-12 16:16 ET
CEL-SCI Corporation published news for 2020 q4
SEC form 6
2020-12-30 17:36 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-30 17:17 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-30 17:16 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 10
2020-12-29 17:01 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-29 17:00 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-09 17:05 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-07 18:00 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-10-30 16:17 ET
CEL-SCI Corporation published news for 2020 q3